Silence Therapeutics (SLNCF) Stock Price, News & Analysis

Company Overview

Silence Therapeutics plc is a biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. Its approach is designed to target specific messenger RNA molecules before they are translated into proteins, potentially enabling treatments for conditions that are difficult to address with conventional therapies.

The company’s proprietary mRNAi GOLD platform supports the design and delivery of small interfering RNA (siRNA) medicines, including compounds intended to target tissues outside the liver. Its research and development programs have included zerlasiran (SLN360), an investigational therapy designed to reduce lipoprotein(a), and divesiran (SLN124), an investigational treatment being developed for certain hematologic disorders. These programs have been evaluated in clinical studies, subject to regulatory review and further development.

Silence Therapeutics was established in the United Kingdom and was formerly known as SR Pharma before adopting its current name. The company operates in the international biopharmaceutical market, conducting research and clinical-development activities intended to support potential commercialization across multiple geographies. Its work is focused primarily on advancing RNAi-based therapies through partnerships and internal development programs.

Key Stats

• Today's Range: $4.00 to $4.00
• 50-Day Range: $1.50 to $5.99
• 52-Week Range: $1.06 to $5.99
• Volume: N/A
• Average Volume: 1,761 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SLNCF
• CIK: 1479615
• Web: www.silence-therapeutics.com
• Phone: 442034576900
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A